No Statin is Free from UTI Risk, But the Association is Weak and Inconsistent
The evidence does not support that any specific statin is definitively free from urinary tract infection (UTI) associations as a side effect. However, the relationship between statins and UTIs appears to be minimal, inconsistent across studies, and not a recognized major adverse effect in clinical practice.
What the Evidence Shows
Statin-Associated UTI Risk is Small and Contradictory
The available research presents conflicting findings:
- Pravastatin showed the strongest signal for storage lower urinary tract symptoms (LUTS) in prescription database mining 1, with adjusted sequence ratios suggesting increased use of medications for storage symptoms after pravastatin initiation
- However, pravastatin paradoxically reduced recurrent UTIs in the PREVEND IT trial, with a 57% reduction in total UTI antibiotic prescriptions and 75% reduction in second (recurrent) UTI prescriptions 2
- Analysis of FDA adverse event data found small but statistically significant signals for LUTS with rosuvastatin, atorvastatin, simvastatin, pravastatin, pitavastatin, and lovastatin 3
- A 2025 observational study in type 2 diabetes patients found statins were the second most commonly prescribed medication class before UTI diagnosis (3.42 percentage point difference), though this was an association study, not causation 4
The Clinical Reality
UTIs are not listed as a recognized adverse effect in major statin guidelines 5, 6, 7, 8. The 2013 Canadian consensus on statin adverse effects extensively reviewed side effects including myopathy, hepatotoxicity, diabetes, and renal effects (hematuria/proteinuria from tubular interference), but did not identify UTIs as a clinically significant concern 9.
Key Caveats and Clinical Considerations
Why This Association May Not Be Causal
- Confounding by indication: Patients on statins have cardiovascular disease and diabetes—conditions independently associated with increased UTI risk
- The signals are weak: Reporting odds ratios of 1.16-1.25 represent minimal increases 3
- Mechanism unclear: No plausible biological mechanism has been established linking statins to UTIs
- Contradictory evidence: Pravastatin both increased LUTS prescriptions in one study 1 and decreased recurrent UTIs in another 2
What Matters More for UTI Risk
The evidence suggests that other factors are far more important for UTI risk in patients requiring statins:
- Diabetes mellitus (the primary indication for many statin users)
- Female gender
- Postmenopausal status
- Urological abnormalities
- Immunosuppression
Practical Recommendation
Do not select or avoid any particular statin based on UTI concerns. Choose your statin based on:
- Cardiovascular risk reduction efficacy
- LDL-cholesterol lowering potency needed
- Drug interactions
- Renal clearance considerations (pitavastatin, pravastatin, rosuvastatin have partial renal clearance; atorvastatin and fluvastatin are hepatically cleared) 6
- Established adverse effects (myopathy, hepatotoxicity, diabetes risk)
If a patient on a statin develops recurrent UTIs, investigate and manage according to standard UTI guidelines 10—the statin is unlikely to be the culprit and should not be discontinued for this reason alone.